High plasma level of interleukin-18 in HIV-infected subjects with lipodystrophy

被引:32
作者
Lindegaard, B
Hansen, ABE
Gerstoft, J
Pedersen, BK
机构
[1] Univ Copenhagen, Rigshosp, Dept Infect Dis, DK-2100 Copenhagen O, Denmark
[2] Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark
关键词
interleukin-18; HIV; antiretroviral therapy; lipodystrophy;
D O I
10.1097/00126334-200405010-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The level of interleukin-18 (IL-18) is elevated inpatients with HIV infection as well as in people with insulin resistance (IR). As HIV-associated lipodystrophy (LD) shares metabolic characteristics with the metabolic syndrome, it was hypothesized that IL-18 would be elevated in patients with LD. Two groups of HIV-infected men with LD, one with fat accumulation (mixed group) (n = 12) and one without fat accumulation (lipoatrophic group) (n = 15) were included. Controls were HIV-positive men without LD (n = 15) and HIV-negative, age-matched men (n = 12), The levels of plasma IL-18 were elevated in all 3 HIV groups compared with HIV-negative controls (P <0.01). In the HIV groups the lipoatrophic group had the highest IL-18, followed by the mixed group and the HIV-positive controls. Only the differences between the lipoatrophic group and the HIV-positive controls were significant (P <0.01). Plasma IL-18 correlated with tumor necrosis factor-alpha (P <0.05), but not IL-6, adiponectin, or HOMA-IR (homeostasis model of insulin resistance). In contrast to the HIV-negative controls, IL-18 did not correlate with total or low-density cholesterol in either of the HIV groups. An inverse correlation was observed between IL-18 and limb fat (P<0.05) In conclusion, the level of IL-18 is elevated in patients with LD and closely linked to limb atrophy, whereas it is not associated with cholesterol or IR.
引用
收藏
页码:588 / 593
页数:6
相关论文
共 45 条
[1]   Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy:: Persistent TNF activation is associated with virologic and immunologic treatment failure [J].
Aukrust, P ;
Müller, F ;
Lien, E ;
Nordoy, I ;
Liabakk, NB ;
Kvale, D ;
Espevik, T ;
Froland, SS .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :74-82
[2]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[3]   Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs - The Swiss HIV cohort study [J].
Bernasconi, E ;
Boubaker, K ;
Junghans, C ;
Flepp, M ;
Furrer, HJ ;
Haensel, A ;
Hirschel, B ;
Boggian, K ;
Chave, JP ;
Opravil, M ;
Weber, R ;
Rickenbach, M ;
Telenti, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (01) :50-55
[4]   Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina [J].
Blankenberg, S ;
Tiret, L ;
Bickel, C ;
Peetz, D ;
Cambien, F ;
Meyer, J ;
Rupprecht, HJ .
CIRCULATION, 2002, 106 (01) :24-30
[5]   Interaction between free fatty acids and glucose metabolism [J].
Boden, G .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2002, 5 (05) :545-549
[6]   An objective case definition of lipodystrophy in HIV-infected adults: a case-control study [J].
Carr, A ;
Emery, S ;
Law, I ;
Puls, R ;
Lundgren, JD ;
Powderly, WG ;
Carr, B ;
Cooper, DA ;
Grinspoon, S ;
Ioannidis, J ;
Lewis, R ;
Law, M ;
Lichtenstein, K ;
Murray, J ;
Pizzuti, D ;
Rozenbaum, W ;
Schambelan, M ;
Moore, A ;
Miller, J .
LANCET, 2003, 361 (9359) :726-735
[7]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[8]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[9]   A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].
Carr, A ;
Miller, J ;
Law, M ;
Cooper, DA .
AIDS, 2000, 14 (03) :F25-F32
[10]   Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance [J].
Carr, A ;
Samaras, K ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1998, 351 (9119) :1881-1883